Superoxide dismutase and its use for preventing or treating dry eye
Oral administration of SOD from Bacillus amyloliquefaciens addresses the limitations of current dry eye treatments by enhancing tear secretion and reducing inflammation, offering a safer and more effective long-term solution.
Patent Information
- Application Number
- JP2024538978
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-15
- Filing Date
- 2022-05-16
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for dry eye, such as artificial tear agents and anti-inflammatory eye drops, provide only temporary relief and can cause side effects, while long-term use of immunomodulators like Restasis ophthalmic solution is necessary for efficacy and has a high burning sensation rate, lacking a safe and effective long-term solution.
Superoxide dismutase (SOD) derived from Bacillus amyloliquefaciens, administered orally, to reduce inflammation and increase tear secretion, stabilizing the tear film and protecting ocular surface cells.
SOD effectively increases tear secretion, extends tear film breakdown time, reduces ocular surface damage, and minimizes inflammatory responses, providing a safer and more fundamental treatment for dry eye compared to existing methods.
Smart Images

Figure 2024545353000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a superoxide dismutase and its use for the prevention, amelioration or treatment of dry eye. More specifically, the present invention relates to a superoxide dismutase, composition or method for the prevention, amelioration or treatment of dry eye. [Background technology]
[0002] Dry eye is a major disease with a high incidence in Korean adults, affecting approximately 20% of all adults. Recently, the concept of dry eye has changed and it is now defined as a multifactorial disease of the tear film and ocular surface that causes discomfort, visual impairment, tear film instability, and damage to the ocular surface, accompanied by increased tear osmolarity and ocular surface inflammation.
[0003] Although the pathological mechanism of dry eye development has not yet been clearly elucidated, it is related to inflammatory changes on the ocular surface due to hyperosmolarity of tears, and various studies have reported that various inflammatory factors contribute not only to the pathological progression of dry eye but also to ocular discomfort. In Sjögren's syndrome patients, the expression of inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, and IFN-γ in the tears and conjunctival epithelium, immune activity and adhesion substances in conjunctival epithelial cells such as HLA-DR and ICAM-1, and cytokines related to the Th-1 or Th-17 inflammatory pathways is increased. In addition, the concentration and activity of matrix metalloproteinase is increased in dry eye, and cell apoptosis of the ocular surface epithelium is increased, revealing that dry eye is directly related to inflammation on the ocular surface. Therefore, it is important to suppress inflammation on the ocular surface due to hyperosmolarity of tears in order to treat dry eye.
[0004] Currently, the treatments for dry eye include environmental adjustment, artificial tears, anti-inflammatory treatments such as steroids or cyclosporine, lacrimal secretion promoters, lacrimal punctum occlusion, serum eye drops, therapeutic contact lenses, and surgery, and are selected according to the severity of the disease, but there is currently no reliable treatment. Among these, the mixed administration of artificial tears and anti-inflammatory eye drops is the most widely used drug treatment method for treating dry eye. Although artificial tears can temporarily relieve the symptoms of dry eye, they cannot fundamentally treat inflammation on the ocular surface, and among anti-inflammatory preparations, steroids have the disadvantage of potentially causing serious complications such as glaucoma and cataracts, so there is a need to develop new treatments for dry eye.
[0005] Meanwhile, in 2006, Allergan, Inc. of the United States, developed Restasis eye drops, a treatment for dry eye disease that uses cyclosporine, an immunomodulator. Restasis eye drops have been reported to suppress the production and activation of immune cells related to keratoconjunctivitis sicca and increase tear secretion. However, since the drug exerts its efficacy through its anti-inflammatory action, it needs to be used repeatedly for several months to achieve a satisfactory level of efficacy, and there is a problem that the typical side effect, a burning sensation, occurs in about 17% of cases.
[0006] Therefore, there is a need to develop a preparation that is safe with a low incidence of side effects when administered by eye drop, and that is not merely a symptomatic treatment that relieves symptoms, but can more fundamentally prevent or treat dry eye disease. Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to solve the above-mentioned problems of the conventional technology. Another object of the present invention is to provide a superoxide dismutase for the prevention, amelioration or treatment of dry eye. Another object of the present invention is to provide a superoxide dismutase derived from Bacillus amyloliquefaciens that ensures efficacy and safety when orally administered for the prevention, amelioration or treatment of dry eye. Another object of the present invention is to provide a Bacillus-derived or Bacillus amyloliquefaciens-derived superoxide dismutase that is conveniently secreted extracellularly for production for the prevention or treatment of dry eye. Another object of the present invention is to provide a pharmaceutical composition or a method for preventing or treating dry eye. Another object of the present invention is to provide a food or feed composition for the prevention or amelioration of dry eye. Another object of the present invention is to provide a composition for oral administration comprising superoxide dismutase for the prevention, amelioration or treatment of dry eye. The object of the present invention is not limited to the above object. The object of the present invention will become clearer from the following description and can be realized by the means and combinations thereof described in the claims. [Means for solving the problem]
[0008] A representative configuration of the present invention for achieving the above object is as follows. According to one embodiment of the present invention, there is provided an improved superoxide dismutase (SOD) for the prevention, amelioration or treatment of dry eye.
[0009] According to another embodiment of the present invention, there is provided a superoxide dismutase derived from a generally regarded as safe (GRAS) bacterium, such as Bacillus, for the prevention, amelioration or treatment of dry eye.
[0010] According to another embodiment of the present invention, there is provided a Bacillus-derived or Bacillus amyloliquefaciens-derived superoxide dismutase that is conveniently secreted extracellularly for production for the prevention, amelioration or treatment of dry eye.
[0011] According to another embodiment of the present invention, there is provided an improved superoxide dismutase that exhibits a preventive, ameliorative or therapeutic effect on dry eye even when orally administered.
[0012] According to another embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating dry eye, comprising the above-mentioned superoxide dismutase (SOD) as an active ingredient.
[0013] According to another embodiment of the present invention, there is provided a food or feed composition for improving or preventing dry eye, which comprises the above-mentioned superoxide dismutase as an active ingredient.
[0014] According to another embodiment of the present invention, there is provided a composition for oral administration for preventing, ameliorating or treating dry eye, which comprises the above-mentioned superoxide dismutase as an active ingredient.
[0015] According to another embodiment of the present invention, there is provided a method for preventing, ameliorating or treating dry eye, comprising the step of administering the superoxide dismutase or the composition to a subject.
[0016] According to another embodiment of the present invention, there is provided a use of the superoxide dismutase for the prevention or treatment of dry eye.
[0017] According to another embodiment of the present invention, there is provided a use of the superoxide dismutase for producing a medicament for preventing or treating dry eye. Effect of the Invention
[0018] The superoxide dismutase, composition and method according to the present invention can be effectively used to prevent, improve or treat dry eye by any one or more of the following effects: increasing tear secretion, increasing tear film breakup time, minimizing ocular surface damage, protecting conjunctival goblet cells, decreasing the number of corneal and / or conjunctival immune cells and / or inflammatory cytokines, decreasing oxidative stress in the cornea, conjunctiva and / or lacrimal gland, and decreasing corneal epithelial cell death. In particular, it has been confirmed that the superoxide dismutase according to the present invention is effective in preventing, improving or treating dry eye even when administered orally.
[0019] The superoxide dismutase of the present invention is derived from Bacillus or Bacillus amyloliquefaciens, which are bacteria generally regarded as safe (GRAS), and not only ensures efficacy and safety for oral administration, but also has the production advantage of being directly recoverable from the supernatant during cultivation. [Brief description of the drawings]
[0020] [Figure 1] FIG. 1 shows a schematic diagram for the double crossover recombination carried out in Example 1.1. [Diagram 2] The results of confirming the defective gene by PCR in the expression host GFBS220 and the production strain BSBA310 are shown. W indicates the wild-type B. subtilis KCTC 3135, 220 indicates the expression host GFBS220, and 310 indicates the SodA2 production strain BSBA310. [Diagram 3] FIG. 1 is a diagram showing a comparison of the amino acid sequences of SodA (Mn-SOD identified by N-terminal sequencing from the culture supernatant of Bacillus amyloliquesfaciens strain GF423) and the superoxide dismutase of the present invention (SodA2). [Figure 4]The expression vector for overexpression of sodA2 gene is shown, where rrnB T1T2 represents a transcription terminator, rep(pBR322) represents a replicon from pBR322 that functions in E. coli, rep(pUB110) represents a replicon from pUB110 that functions in B. subtilis, KanR represents a kanamycin resistance gene (aminoglycoside O-nucleotidyltransferase), and BJ27 promoter represents a strong promoter for B. subtilis. [Diagram 5] FIG. 1 shows the overall procedure for producing the production strain BSBA310. [Figure 6] FIG. 2 is a diagram showing the results of measurement of tear volume performed in an embodiment of the present invention. [Figure 7] FIG. 2 is a diagram showing the results of measurement of tear film break-up time (TBUT) performed in an embodiment of the present invention. [Figure 8] FIG. 2 is a diagram showing the results of measurement of corneal fluorescent staining score performed in an embodiment of the present invention. [Figure 9] FIG. 1 shows the results of measuring the number of immune cells performed in an example of the present invention. [Figure 10] FIG. 2 is a diagram showing the results of active oxygen generation carried out in an embodiment of the present invention. [Figure 11] FIG. 2 is a diagram showing the results of measuring the number of conjunctival goblet cells carried out in an embodiment of the present invention. [Figure 12] FIG. 1 shows the results of cell death measurements carried out in an example of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] The detailed description of the present invention described below will be described with reference to certain drawings of specific embodiments in which the present invention can be practiced, but the present invention is not limited thereto, and is limited only by the appended claims, if properly described, and to the full extent of equivalents thereto. It should be understood that the various embodiments of the present invention are different from each other, but are not necessarily mutually exclusive. For example, the specific shapes, structures, and characteristics described herein can be changed from one embodiment to another, or implemented in combination with the embodiments, without departing from the spirit and scope of the present invention. The terms presented in describing the present invention should generally be understood as their ordinary meanings, unless otherwise specified, and apply to all the same terms used herein, as well as to the aspects or embodiments of the invention in which the terms are defined. For purposes of interpreting this specification, the following definitions apply, and terms used in the singular form include the plural form where appropriate, and vice versa.
[0022] definition The term "about" as used herein refers to the normal range of error for the respective value known to one of ordinary skill in the art.
[0023] The term "subject" is used interchangeably with "patient" and may refer to a mammal in need of prevention or treatment of dry eye, such as primates (e.g., humans), pets (e.g., dogs, cats, etc.), livestock animals (e.g., cows, pigs, horses, sheep, goats, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). In one embodiment of the invention, the subject is a human.
[0024] The term "treatment" includes preventive and / or therapeutic treatments. The preventive and / or therapeutic treatments include any type of treatment recognized in the art, including, for example, administering the pharmaceutical composition or SOD of the present invention to a subject. When administered prior to clinical manifestation of an undesirable or unwanted condition (e.g., a disease or other undesirable or unwanted condition in a subject), such treatment or treatment is a preventive treatment or treatment (e.g., protecting the subject from the development of an undesirable or unwanted condition in the subject). On the other hand, when administered after clinical manifestation of an undesirable or unwanted condition, such treatment or treatment is a therapeutic treatment, such as reducing, alleviating or stabilizing an existing undesirable or unwanted condition or its side effects.
[0025] The meaning of the term "prevention" is well known in the art. When used in relation to a medical condition such as dry eye, it means that administration of the pharmaceutical composition or SOD of the present invention reduces the frequency or delays the onset and symptoms of the medical condition (e.g., discomfort, blurred vision, tear film instability, ocular surface damage, increased tear osmolality, ocular surface inflammation, etc.) compared to a subject not receiving the pharmaceutical composition or SOD.
[0026] The term "administering" means providing an active ingredient to a subject to achieve a prophylactic or therapeutic objective (eg, prevention or treatment of dry eye).
[0027] Dry eyes The present invention is based, at least in part, on the discovery that administration, particularly oral administration, of superoxide dismutase (SOD) is effective in preventing or treating dry eye. Thus, according to one embodiment of the present invention, there is provided a use of SOD for preventing, ameliorating or treating dry eye.
[0028] The term "dry eye" is used interchangeably with dry eye or dry eye disease and refers to an eye disease that exhibits various symptoms, such as ocular discomfort, dryness, foreign body sensation, itchiness, pain, and decreased vision, due to various causes, such as insufficient tears, excessive evaporation of the tear film, imbalance of tear components, and damage to the ocular surface due to inflammatory changes in tissues involved in the tear secretion process.
[0029] In the present invention, dry eye may also be caused by other underlying diseases such as Sjogren's syndrome, or may be a complication of blepharitis or a foreign body in the eye. In the present invention, dry eye may also be the result of an infection, a side effect of medication, or the result of exposure to toxins, chemicals, or other substances. Thus, dry eye in the present invention may include both dry eye due to Sjogren's syndrome and dry eye due to non-Sjogren's syndrome.
[0030] The SOD according to the present invention can result in one or more of the following: increased tear secretion, increased tear film breakup time, minimization of ocular surface damage, protection of conjunctival goblet cells, reduction in the number of corneal and / or conjunctival immune cells and / or inflammatory cytokines, reduction in oxidative stress in the cornea, conjunctiva and / or lacrimal gland, and reduction in corneal epithelial cell death.
[0031] Superoxide dismutase (SOD) According to another embodiment of the present invention, there is provided an improved superoxide dismutase (SOD) for the prevention, amelioration or treatment of dry eye.
[0032] Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of superoxide radicals (O2-) into general molecular oxygen (O2) and hydrogen peroxide (H2O2), and SOD plays an important role in scavenging reactive oxygen species and reducing oxidative stress. SODs are widely distributed in prokaryotic and eukaryotic cells and are classified into four classes according to the different types of metal centers (copper / zinc, nickel, manganese, and iron). Manganese-containing SOD [Mn-SOD] is widely present in various bacteria, chloroplasts, mitochondria, and cytoplasm of eukaryotic cells. The term "SOD" can be used interchangeably with polypeptides that have superoxide dismutase activity.
[0033] In one embodiment, the SOD may be manganese-binding type (Mn-SOD). Specifically, the SOD may be deamidated Mn-SOD. More specifically, the SOD may have amino acid residues at positions 73 and 136 of SEQ ID NO: 2 substituted with Asp. More specifically, the SOD may include or consist of the amino acid sequence shown in SEQ ID NO: 4.
[0034] The SOD or polypeptide having SOD activity of the present invention is also understood to include an amino acid sequence showing substantial identity to the above amino acid sequence. The term "substantial identity" means an amino acid sequence showing 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 98% or more sequence identity when the aligned sequences are analyzed using an algorithm commonly used in the art.
[0035] In other embodiments, the SOD is a modified or engineered polypeptide having SOD enzymatic activity and may contain one or more mutations, e.g., deletion, insertion, or substitution of one or more amino acids, that may or may not affect various aspects (in vivo, in vitro, or ex vivo stability, homogeneity, and / or morphological changes). Additionally, the polypeptide may further contain a heterologous substance (e.g., tags known in the art, including HIS tag, Ha tag, myc tag, GFC and / or Fc domain of an antibody) for enhancing purification, detection, or stability.
[0036] In one embodiment, the SOD may be an enzyme derived from a natural or recombinant microorganism, or may be produced through processes that have been isolated or purified from a variety of sources.
[0037] In one embodiment, the SOD may be derived from a natural or recombinant microorganism. For example, the SOD may be derived from a bacterium. Preferably, the SOD may be sourced from a bacterium that is generally regarded as safe (GRAS) for use in drugs or foods. Specifically, the SOD may be derived from a Bacillus species strain. More specifically, the SOD may be derived from a Bacillus amyloliquefaciens strain. For example, the SOD may be derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222 BP). The GF423 strain (KCTC 13222 BP) was deposited at the Korea Institute of Bioscience and Biotechnology on March 6, 2017. The SOD may also be derived from a recombinant strain comprising the expression vector shown in FIG. 4. The SOD may also be derived from a recombinant strain produced by a method comprising the method shown in FIG. 5. The recombinant strain may be a Bacillus sp. strain comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and deleted in the following genes: AprE, NprE, Bpr, Epr, NprB, Vpr, Mpr, IspA, SrfAC, spoIIAc, EpsE and Xpf. For detailed process for producing the strain, see Example 1.
[0038] Since the SOD derived from the above-mentioned strain is an enzyme secreted extracellularly, when SOD is produced using the above-mentioned strain, it is possible to mass-produce SOD that is safe for humans without going through an expensive purification process (e.g., column purification), thereby enabling efficient production.
[0039] In one embodiment, SOD may be isolated or purified from various sources, including natural or recombinant hosts. For example, SOD having activity in preventing or treating dry eye can be extracted from the culture supernatant of Bacillus amyloliquefaciens strain GF423. Briefly, Bacillus amyloliquefaciens strain GF423 can be cultured in various types of media to obtain culture media. For example, the strain is grown at about 25°C to about 42°C for about 1 day to about 4 days using a complex medium (pH 6.0 to 7.0). Other suitable media for culturing Bacillus amyloliquefaciens strain GF423 include Luria-Bertani (LB) medium, International Streptomyces Project (ISP) medium, nutrient agar (NA) medium, brain heart infusion agar (BHI) medium, sabouraud dextrose agar (SDA) medium, potato dextrose agar (PDA) medium, nutrient broth (NB) medium, etc. Preferably, LB medium, ISP medium, BHI medium, SDA medium, or NB medium may be used. Furthermore, SOD can be supplied from other natural or recombinant hosts using information provided in databases such as PubMed or BRENDA (brenda-enzymes.org on the world wide web).
[0040] In one embodiment, the SOD may be an isolated or purified enzyme, where the isolated or purified SOD or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which it is derived. For example, the purified product may be isolated in pure form from a culture of a strain by ultrafiltration, ammonium sulfate treatment, column purification, concentration, etc., or may be a culture retentate obtained by ultrafiltration, concentration, etc. The term "substantially free of cellular material" includes preparations of a protein in which such a protein has been separated from cellular components of the cells from which the protein is isolated or from which the protein is recombinantly produced. In one embodiment, the term "substantially free of cellular material" includes preparations of a protein having less than about 30%, preferably less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of undesired protein by dry weight.
[0041] In another embodiment, it may be desirable to purify SOD by the following purification method, including but not limited to the following: Bacillus amyloliquefaciens strain GF423 is cultured, and the resulting culture broth is centrifuged to collect the culture supernatant. The supernatant fraction is pretreated by solid phase extraction, and then separated and purified by chromatography. In this case, SOD may be purified using various types of chromatography. Preferably, hydrophobic interaction chromatography is used.
[0042] In another embodiment, the SOD may be included in the form of a strain lysate, a strain culture, a strain culture concentrate, a strain culture extract, or a dried form thereof. In this case, the term "strain lysate" refers to a product obtained by culturing a strain and mechanically or chemically disrupting the strain, and may include any product obtained by additional steps such as extraction, dilution, concentration, purification, etc. The term "strain culture" refers to a culture liquid obtained by culturing a strain or a supernatant thereof. The term "strain culture concentrate" refers to a product separated purely from a strain culture by ultrafiltration, ammonium sulfate treatment, column purification, concentration, etc., or a culture concentrate obtained by ultrafiltration, concentration, etc. The term "strain culture extract" refers to a product extracted from the culture liquid or the concentrate thereof, and may include an extract, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a crude product or purified product thereof, or a fraction obtained by fractionating the same. The dried form may include a freeze-dried form.
[0043] In one embodiment, the SOD of the present invention was orally administered to an individual in need of prevention or treatment of dry eye and showed one or more of the following effects: increased tear secretion, increased tear film breakup time, minimized ocular surface damage, protected conjunctival goblet cells, reduced numbers of corneal and / or conjunctival immune cells and / or inflammatory cytokines, reduced oxidative stress in the cornea, conjunctiva and / or lacrimal gland, and reduced corneal epithelial cell death.
[0044] Pharmaceutical Compositions According to one embodiment of the present invention, there is provided a pharmaceutical composition for treating or preventing dry eye, which comprises superoxide dismutase (SOD) as an active ingredient.
[0045] In one embodiment, the SOD according to the present invention can be combined with a pharma- ceutical carrier, excipient and / or diluent to form a pharmaceutical composition for the prevention or treatment of dry eye. When the pharmaceutical composition of the present invention is applied to animals other than humans, it may be used interchangeably with the term veterinary composition.
[0046] The pharmaceutical or veterinary compositions of the present invention may further comprise one or more selected from the group consisting of pharma- ceutically acceptable carriers, excipients and diluents. The pharma- ceutically acceptable carriers, excipients and / or diluents may be those commonly used in the art. Examples of the carriers, excipients or diluents include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils such as silicon dioxide.
[0047] When the formulation is made, additives such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, etc. may be used for preparation. The additives for the formulation may be appropriately selected from those commonly used in the pharmaceutical field.
[0048] The pharmaceutical or veterinary compositions of the present invention may be formulated in a preferred form depending on the method of use, and may be formulated by employing methods known in the art to provide quick, sustained or delayed release of the active ingredient after administration to a mammal, in particular. Specific examples of such dosage forms include tablets, pills, acids, granules, syrups, liquids, capsules, suspensions, emulsions, injections, plasters, lotions, liniments, limeades, aerosols, extracts, elixirs, ointments, fluid extracts, infusions, creams, soft or hard gelatin capsules, patches, etc.
[0049] Moreover, the pharmaceutical or veterinary compositions of the present invention may be suitably formulated using any suitable method known in the art or as disclosed in Remington's Pharmaceutical Sciences (latest edition), Mack Publishing Company, Easton Pa.
[0050] In one embodiment, the SOD may be administered orally or parenterally. For oral administration, the SOD may be coated with shellac to protect it from stomach acid, but the coating agent is not limited thereto. Examples of coating agents suitable for use in the present invention include shellac, ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, zein, Eudragit, and combinations thereof. When the SOD is coated, the SOD may be coated in solution. Specifically, the purified solution is mixed with a shellac-containing solution and then freeze-dried. The freeze-dried sample becomes a powder and can be stored at about 4°C until use. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid formulations may be prepared by mixing the complex composition with at least one or more excipients, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, liquids for internal use, emulsions, syrups, etc., and in addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, flavorings, preservatives, etc. may be used.
[0051] For parenteral administration, the following injection methods may be selected: sublingual administration, intraocular administration including intravitreal administration, intranasal spray, topical application on the skin, patch, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
[0052] Also, the pharmaceutical or veterinary compositions of the present invention are administered in a pharma- ceutical or veterinarily effective amount. The term "pharmaceutical effective amount" or "veterinarily effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical or veterinary treatment, and the effective dose level can be determined based on factors including the patient's or animal's weight, sex, age, health condition, severity, drug activity, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical arts.
[0053] The pharmaceutical or veterinary compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, either sequentially or simultaneously. The pharmaceutical compositions may be administered in single or multiple doses as needed. It is important to administer an amount that provides maximum efficacy at a minimum dose without side effects, taking into account all of the above factors, and such an amount can be readily determined by one of skill in the art.
[0054] Preventive or therapeutic methods According to another embodiment of the present invention, there is provided a method for treating or preventing dry eye, comprising the step of administering an SOD or a pharmaceutical composition according to the present invention to a subject having or at risk of having dry eye.
[0055] Also provided is a method for treating or preventing dry eye, comprising administering superoxide dismutase to a subject. The details regarding SOD, dry eye, and treatment or prevention are as described above for the pharmaceutical composition.
[0056] The term "administration" includes any of various administrations that enable treatment by performing the intended action. The administration may include oral administration. For oral administration, see the description of the pharmaceutical composition above. The administration route may be oral, parenteral, inhalation, topical or local administration (e.g., intralesional administration). For example, parenteral administration may include, but is not limited to, intravenous, subcutaneous, intraperitoneal, intraarterial, and intraocular administration. In the case of oral administration, SOD may be administered in a form coated with a coating agent such as shellac, as described above.
[0057] The effective amount or effective non-toxic amount of SOD according to the present invention can be determined by routine experimentation. For example, the therapeutically active amount of SOD according to the present invention may vary depending on factors such as the stage of the disease, the severity of the disease, the age, sex, medical complications, and weight of the subject. The dosage and administration regimen of SOD according to the present invention may be adjusted to provide an optimal therapeutic response. For example, several divided doses may be administered daily, weekly, every two weeks, every three weeks, every four weeks, etc., or the dosage may be proportionally reduced or increased depending on the exigencies of the therapeutic situation.
[0058] In one embodiment, the method may include administering one or more additional agents for treating or preventing dry eye. The one or more additional agents may be administered simultaneously, sequentially, or in reverse order with the SOD or pharmaceutical composition. Additionally, the individual components may be administered to a subject by the same route or by different routes.
[0059] Food Composition According to another embodiment of the present invention, there is provided a food composition for improving or preventing dry eye, which contains superoxide dismutase (SOD) as an active ingredient. Such a food composition includes a medical or nutraceutical food composition.
[0060] The term "medical food" or "nutraceutical food" is defined by the Ministry of Food and Drug Safety as a food made from ingredients or components that may have beneficial functions on the human body and that maintains or improves health by maintaining normal functions or activating physiological functions of the human body, but is not limited thereto and does not exclude any ordinary health food from its meaning.
[0061] In addition, the food products include, but are not limited to, various foods, food additives, beverages (e.g., functional beverages, natural fruit juice and vegetable beverages), gums, teas, vitamin complexes, health functional foods, and other functional foods.
[0062] The food may be prepared by a conventional method known in the art. For example, the medical food, nutraceutical food, or health functional food may further contain one or more of carriers, diluents, excipients, and additives in addition to the SOD, and may be formulated into one selected from the group consisting of tablets, pills, acidulants, granules, powders, capsules, and liquid dosage forms, for the purpose of preventing or improving dry eye. Specific examples of the carriers, excipients, diluents, and additives are well known in the art, and those skilled in the art may prepare them by combining appropriate ingredients according to the dosage form.
[0063] The content of the superoxide dismutase according to the present invention as an active ingredient in the above-mentioned dosage form may be appropriately adjusted depending on the form and purpose of use, the condition of the patient, the type and severity of symptoms, etc., and may be about 0.001 to about 99.9 wt% based on the solid content weight, preferably about 0.01 to about 50 wt%, but is not limited thereto.
[0064] The dosage of the food of the present invention varies depending on the age, weight, sex, dosage form, health condition and severity of the disease of the patient, and may be administered once or several times a day at regular intervals at the discretion of a doctor or pharmacist. For example, the daily dosage may be 10 to 1000 mg / kg based on the content of the active ingredient. The above dosage is an example of an average case, and the dosage may be higher or lower depending on individual differences. If the daily dosage of the health functional food of the present invention is less than the above dosage, it may not be possible to obtain a meaningful effect, and if it is more than the above dosage, it is not only uneconomical but also exceeds the range of the normal dosage, and undesirable side effects may occur.
[0065] Feed composition According to another embodiment of the present invention, there is provided a feed composition for preventing or improving dry eye, which contains the SOD according to the present invention as an active ingredient. In the present invention, the food composition may include a feed composition. Such a feed composition may be prepared in any dosage form commonly used in the art. For example, the feed composition of the present invention may further include supplementary ingredients such as amino acids, inorganic salts, vitamins, antibiotics, antibacterial substances, antioxidants, antifungal enzymes, and other live microbial preparations; grains such as crushed or shredded wheat, oats, barley, corn, and rice; vegetable protein feeds such as those based on rapeseed, soybeans, and sunflower; animal protein feeds such as blood meal, meat meal, bone meal, and fish meal; dry ingredients consisting of sugar and dairy products such as various types of milk powder and whey powder; lipids such as animal fats and vegetable fats optionally liquefied by heating; and additives such as nutritional supplements, digestive and absorption improvers, growth promoters, and disease preventive agents.
[0066] The feed composition of the present invention may be in the form of a powder or liquid formulation, and may contain a feed additive excipient (for example, calcium carbonate, powdered powder, zeolite, egg powder, rice bran, etc.).
[0067] Polynucleotides, expression vectors and host cells In accordance with another embodiment of the present invention, there is provided a polynucleotide encoding the superoxide dismutase polypeptide, specifically a nucleic acid encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:4.
[0068] According to another embodiment of the present invention, there is provided an expression vector comprising the nucleic acid. Specifically, the vector may be the expression vector shown in FIG.
[0069] According to another embodiment of the present invention, there is provided a host cell comprising said nucleic acid or said expression vector. In particular, said host cell is a bacterial cell. More particularly, said host cell is a strain of Bacillus sp.
[0070] According to another embodiment of the present invention, there is provided a Bacillus sp. strain comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and deleted in the following genes: AprE, NprE, Bpr, Epr, NprB, Vpr, Mpr, IspA, SrfAC, spoIIAc, EpsE and Xpf. For detailed process for producing said strain, see Example 1 below.
[0071] The present invention will now be described in more detail with reference to the following examples, which are presented to aid in the understanding of the present invention and are not intended, and should not be construed as, limiting its scope in any manner.
[0072] Example 1. Preparation of recombinant strain expressing superoxide dismutase (SodA2) Example 1.1. Construction of expression host GFBS220 The expression host GFBS220 was produced using Bacillus subtilis KCTC 3135. B. subtilis KCTC 3135 was provided by the Korea Comprehensive Biotechnology and Technology Center (KCTC), Korea Institute of Bioscience and Biotechnology. To facilitate downstream processing, the genes shown in Table 1 below were deleted from the genome of B. subtilis KCTC 3135.
[0073] [Table 1]
[0074] The gene was removed by double cross-over recombination on the genome (Figure 1). Specifically, DNA fragments (up and down frags) that are homologous to the DNA base sequences on both sides of the gene to be manipulated were cloned into the vector pUCori-ts-cm, which has a temperature-sensitive replication origin. The PCR conditions and primers used for cloning are shown in Tables 2 and 3, respectively.
[0075] [Table 2]
[0076] [Table 3]
[0077] The vector thus prepared was introduced into B. subtilis cells, and transformants (single crossover homologous recombination) were selected using a chloramphenicol-containing medium at 37°C (non-replicative temperature). The selected transformants were cultured in LB medium without antibiotics at 30°C (permissive temperature for replication) (second crossover), and then cultured in LB agar medium without antibiotics at 39°C. The resulting colonies were screened for chloramphenicol-sensitive strains (plasmid curing). PCR was performed on the selected colonies to obtain double crossover recombinants, and a second pure isolation was performed to select the final recombinant, which was named GFBS220.
[0078] The deleted gene site of GFBS220 was amplified using PCR with the primers shown in Table 4, and then confirmed using agarose gel electrophoresis. The results of confirming the deleted gene using PCR in the expression host GFBS220 are shown in Figure 2.
[0079] [Table 4]
[0080] Example 1.2. Construction of expression vector pBE1-sodA2 Mn-SOD was identified from the culture supernatant of Bacillus amyloliquesfaciens strain GF423 by N-terminal sequencing (Kang et al., 2018). The GF423 strain was deposited at the Korea Center for Biotechnology and Technology (KCTC) on March 6, 2017 (Accession No. KCTC 13222 BP). The gene for Mn-SOD was named sodA according to the nomenclature of bacterial SOD, and its amino acid sequence is shown in FIG. 3 and SEQ ID NO: 2 (its nucleotide sequence is shown in SEQ ID NO: 1). LC-UV-MS / MS peptide mapping of the enzyme preparation produced 100% amino acid sequence coverage, but deamidation was observed at Asn73 and Asn136 residues with abundances of 73% and 17%, respectively. Therefore, to improve the homogeneity of the purified enzyme, both Asn residues were replaced with Asp. The amino acid sequence of this mutant sodA, designated SodA2, is shown in FIG. 3 and SEQ ID NO:4 (its nucleotide sequence is shown in SEQ ID NO:3).
[0081] The sodA2 gene was amplified using overlap extension PCR with four primers (Table 5) and the B. amyloliquefaciens GF423 genome as template. Nucleotides for Asn to Asp substitution are underlined.
[0082] [Table 5]
[0083] The amplified DNA fragment containing the sodA2 gene and plasmid pBE1 linearized by NdeI and HindIII treatment were assembled in vitro by the SLIC method (reference [Jeong et al. 2012]), and then the resulting construct was transformed into E. coli C2984H. Correct clones were screened by restriction enzyme mapping and confirmed by nucleotide sequencing. The expression vector thus generated, pBE1-sodA2, is shown in Figure 4.
[0084] Example 1.3. Construction of production strain BSBA310 The expression vector pBE1-sodA2 was transformed into B. subtilis GFBS220. A strain was selected from the transformants, and a pure clone was established by two single colony isolation procedures in LB2 medium. The selected strain was named BSBA310 and stored at -80°C in glycerol stock method. The defective gene was confirmed from this production strain BSBA310 using PCR, and the result is shown in Figure 2. Also, the whole procedure for producing the production strain BSBA310 is summarized in Figure 5.
[0085] Example 2. Isolation and purification of superoxide dismutase (SodA2) from the production strain BSBA310 Example 2.1. Cultivation of the production strain BSBA310 To cultivate the production strain BSBA310 obtained in Example 1, a single colony formed on LB agar medium (LB (Luria-Bertani) agar; tryptophan 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, agar 15 g / L) was inoculated into 30 ml of LB medium and cultured at 37° C. for 12 hours. This seed culture was again inoculated into 3 L of LB medium containing 1 mM manganese sulfate (MnSO4) and cultured at 37° C. for 20 hours.
[0086] Example 2.2. Isolation and purification of SodA2 The cell culture obtained in Example 2.1 was centrifuged at 4°C and 3,578 x g for 20 minutes to collect the supernatant, which was then concentrated 10 times using ultrafiltration (UF, MWCO 10,000). 390 g of ammonium sulfate was added per 1 L of concentrated cell culture, stirred for 20 minutes, and centrifuged to collect the supernatant. The collected supernatant was purified using a phenyl sepharose HP column. The purification process was performed by equilibrating the column using 50 mM potassium phosphate pH 7.0 with a concentration of 2 M ammonium sulfate, then adding ammonium sulfate to pass the resulting supernatant through the column, and recovering the SodA2 attached to the column using 50 mM potassium phosphate pH 7.0 containing 1.6 M ammonium sulfate. The purified solution purified through the column was collected, and the high concentration salt formed during the purification process was removed through ultrafiltration, followed by concentration. The concentrated solution was filtered through a sterilization filter and then freeze-dried. The activity of SodA2 was analyzed using an SOD assay kit (Cayman Chemical, Michigan, USA). One unit of SOD activity is defined as the amount of enzyme that inhibits 50% of superoxide radicals. The activity of the dried SodA2 enzyme was 1000-1200 U / mg.
[0087] Example 3. Preparation of dosage materials Shellac (EXCELACS co., LTD., Bangkok) was dissolved in ethanol to a concentration of 3% and sterilized using a 0.2um sterile filter. The shellac dissolved in ethanol was diluted with PBS. Freeze-dried SodA2 was dissolved at 20mg / ml, and the shellac solution and SOD solution were mixed at a 1:1 ratio and then freeze-dried. The freeze-dried shellac-coated SodA2 was mixed with dextrin at a ratio of 1:9~12 (shellac-coated SodA2:dextrin) to prepare the material used in animal experiments. The SOD activity of the final material was adjusted to 90~110U / mg.
[0088] Example 4. Confirmation of therapeutic or preventive effect on dry eye In this example, we aimed to analyze the effects of oral SodA2 at concentrations of 2.5 mg / kg, 5 mg / kg, and 10 mg / kg on tear secretion, tear film break-up time, ocular surface damage, conjunctival goblet cells, ocular surface inflammatory cytokines, CD4+ T immune cells, oxidative stress and reactive oxygen species, and corneal epithelial cell apoptosis in a C57BL / 6 mouse model induced with experimental dry eye (EDE).
[0089] Example 4.1. Preparation of an Animal Model of Experimental Dry Eye (EDE) To induce experimental dry eye, 7- to 8-week-old C57BL / 6 mice (obtained from Damool Science) were exposed to a ventilator for 18 hours a day and subcutaneously injected with 0.5 mg / 0.2 ml of scopolamine hydrochloride three times a day. Humidity was maintained at 30% and temperature at 25°C. The C57BL / 6 mice were classified into 7 groups according to the concentration of the oral drug administered, as shown in Table 6.
[0090] [Table 6]
[0091] Example 4.2. Drug Administration and Testing Procedures After inducing experimental dry eye in sss experimental mice, the drug prepared in Example 3 was orally administered to the treatment group at 2 μL per dose once a day (administered at 13:30 every day). In both eyes of all mice, the tear secretion volume and tear film breakup time were measured at baseline, 5th day, and 10th day, and the corneal fluorescent dye staining score was investigated. The mice were then sacrificed and tissue analysis was performed. There were 6 animals in each group.
[0092] Measurement of tear volume The tear volume was measured by placing a cotton thread soaked in phenol red in the conjunctival sac on the lateral canthus of the mouse for 20 seconds, measuring its length using SMZ microscopy, and converting it into volume using a set formula (see reference [Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006; 32:272-6]).
[0093] Measurement of tear film break-up time The tear film breakup time was measured to evaluate tear film stability, which is known to be the most important clinical factor in dry eye. After instilling 1 μl of 1% fluorescein into the lower conjunctival sac of the mouse, the mouse was asked to blink about three times and then gently open the eyes. The time (seconds) until the first defect occurred in the stained tear film was measured through a slit lamp equipped with a cobalt blue filter. This was repeated three times and the average value was calculated.
[0094] Measurement of corneal fluorescent staining score After instilling 1 μl of 1% fluorescent staining solution and washing with saline, the mouse cornea was observed under a slit lamp microscope and the degree of epithelial damage (degree of fluorescent staining) was scored. For this purpose, the cornea was divided into four sections, and each section was scored from 0 to 4 points as shown in Table 7, and then the scores were summed up (total score: 0 to 16 points) (see reference [Poly A, Brignole-Baudouin F, Labbe A, Liang H, Warnet JM, Baudouin C: New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci. 2007; 48:5473-83]).
[0095] [Table 7]
[0096] Measurement of Malondialdehyde (MDA) by ELISA Corneas, conjunctivas, and lacrimal glands were excised from six eyes (three mice per group) for both eyes required for tissue analysis. After homogenization of the samples in PBS, the lysates were centrifuged at 10,000 × g for 10 min at 4°C. The supernatants were collected and the total protein content was measured by Bradford assay. MDA was detected using an enzyme-linked immunosorbent assay (ELISA) kit (manufacturer: Quantikine, R&D Systems, Minneapolis, MN) containing capture and detection antibodies according to the manufacturer's instructions. The MDA values of the cornea, conjunctiva, and lacrimal gland were measured by ELISA and recorded, respectively.
[0097] Measurement of inflammatory cytokines using the Luminex multiplex immunobead assay Conjunctival tissue was excised from six eyes (three mice per group) and soaked in lysis buffer containing protease inhibitors for 30 min, centrifuged, and stored at -80°C. The concentrations of IFN-γ, IL-1β, and TNF-α in the cornea and conjunctiva were then analyzed using the Luminex multiplex stained bead assay.
[0098] Measurement of immune cell count and reactive oxygen species (DCF-DA) by flow cytometry The cornea, conjunctiva, and lacrimal gland were excised, torn with scissors, and shaken for 60 minutes at 37°C with 0.5 mg / ml collagenase type D (manufacturer: Roche Applied Science, Indianapolis, IN, USA). The tissue was crushed, passed through a cell strainer, and then centrifuged. Flow cytometry was performed using fluorescein-conjugated anti-CD4 antibody and phycoerythrin-conjugated anti-IFN-γ antibody to count CD4+IFN-γ+ T cells, and the number of DCF-DA cells was calculated using the CM-H2DCFDA kit (manufacturer: Thermo Fisher Scientific, Waltham, MA, USA).
[0099] Histology The eye and associated tissues were removed from one eye of each group, fixed in 4% paraformaldehyde, embedded in paraffin, and stained with PAS on two cross-sections of the tissue. The density of goblet cells in the conjunctiva was calculated from each cross-section using a microscope and image analysis software.
[0100] Immunofluorescent staining The eye and associated tissues were excised from one eye of each group, fixed in 4% paraformaldehyde, embedded in paraffin, and TUNEL staining was performed on two cross-sectional sections of the tissue. The degree of cell death in the conjunctiva was examined for each section using a Leica TCS SP5 AOBS laser scanning confocal microscope (Zeiss GmbH) and image analysis software (NIS Elements version 4.1; Nikon, Melville, NY, USA).
[0101] statistical analysis SPSS 22.0 was used for analysis, and results for continuous variables were expressed as mean ± SD. Normality was confirmed by the Shapiro-Wilk test. Comparisons between groups were performed by one-way analysis of variance (ANOVA) followed by post-hoc analysis with Fisher's LSD post-hoc test. P-values less than 0.05 were considered statistically significant.
[0102] Example 4.3. Results Tear secretion Before drug administration, tear secretion volume was 0.046±0.004 μL in the UT group, 0.023±0.004 μL in the EDE group, 0.024±0.003 μL in the vehicle group, 0.023±0.003 μL in the 0.05% CsA (cyclosporine A) group, 0.024±0.003 μL in the 2.5 mg / kg oral SodA2 group, 0.022±0.004 μL in the 5 mg / kg oral SodA2 group, and 0.023±0.004 μL in the 10 mg / kg oral SodA2 group.
[0103] On the fifth day of administration, the mean mean blood flow was 0.045±0.006 μL in the UT group, 0.02±0.003 μL in the EDE group, 0.021±0.003 μL in the vehicle group, 0.026±0.004 μL in the 0.05% CsA group, 0.026±0.005 μL in the 2.5 mg / kg oral SodA2 group, 0.026±0.005 μL in the 5 mg / kg oral SodA2 group, and 0.026±0.005 μL in the 10 mg / kg oral SodA2 group.
[0104] On the 10th day of administration, the mean mean blood flow was 0.043±0.005 μL in the UT group, 0.017±0.003 μL in the EDE group, 0.018±0.003 μL in the vehicle group, 0.027±0.005 μL in the 0.05% CsA group, 0.027±0.005 μL in the 2.5 mg / kg oral SodA2 group, 0.03±0.005 μL in the 5 mg / kg oral SodA2 group, and 0.028±0.004 μL in the 10 mg / kg oral SodA2 group.
[0105] On the 5th and 10th days of administration, a significant increase in tear secretion was observed in all groups treated with 0.05% CsA, 2.5 mg / kg oral SodA2, 5 mg / kg oral SodA2, and 10 mg / kg oral SodA2 compared to the EDE and vehicle groups, and the 5 mg / kg oral SodA2 group in particular showed a more significant increase than the 0.05% CsA group. The results of the measurement of tear secretion are shown in Figure 6.
[0106] Tear film breakup time The tear film breakup times were 2±0.45 seconds in the UT group before drug administration, 1.43±0.19 seconds in the EDE group, 1.43±0.23 seconds in the vehicle group, 1.46±0.13 seconds in the 0.05% CsA group, 1.44±0.15 seconds in the 2.5 mg / kg oral SodA2 group, 1.42±0.16 seconds in the 5 mg / kg oral SodA2 group, and 1.41±0.25 seconds in the 10 mg / kg oral SodA2 group.
[0107] On the 5th day of administration, the time was 2.21±0.4 seconds in the UT group, 1.02±0.2 seconds in the EDE group, 1.06±0.23 seconds in the vehicle group, 1.3±0.2 seconds in the 0.05% CsA group, 1.23±0.2 seconds in the 2.5 mg / kg oral SodA2 group, 1.31±0.3 seconds in the 5 mg / kg oral SodA2 group, and 1.28±0.3 seconds in the 10 mg / kg oral SodA2 group.
[0108] On the 10th day of administration, the time was 2.1±0.4 seconds in the UT group, 0.91±0.2 seconds in the EDE group, 0.93±0.2 seconds in the vehicle group, 1.39±0.2 seconds in the 0.05% CsA group, 1.21±0.3 seconds in the 2.5 mg / kg oral SodA2 group, 1.28±0.3 seconds in the 5 mg / kg oral SodA2 group, and 1.3±0.3 seconds in the 10 mg / kg oral SodA2 group.
[0109] On days 5 and 10 of administration, the 0.05% CsA, 2.5 mg / kg oral SodA2, 5 mg / kg oral SodA2, and 10 mg / kg oral SodA2 groups all showed a significant increase in tear film breakup time compared to the EDE and vehicle groups, and in particular, the 5 mg / kg oral SodA2 and 10 mg / kg oral SodA2 groups increased the tear film breakup time in a manner similar to that of the 0.05% CsA group. The results of these tear film breakup time measurements are shown in Figure 7.
[0110] Corneal Fluorescence Staining Score The corneal fluorescent dye staining scores before drug administration were 1.8±1.1 points in the UT group, 9.5±1.8 points in the EDE group, 9.1±2 points in the vehicle group, 9.1±2 points in the 0.05% CsA group, 9.2±1.7 points in the 2.5 mg / kg oral SodA2 group, 9.4±1.7 points in the 5 mg / kg oral SodA2 group, and 9.3±1.7 points in the 10 mg / kg oral SodA2 group.
[0111] On the 5th day of administration, the scores were 2.9 ± 1.4 in the UT group, 12.1 ± 2.1 in the EDE group, 11.7 ± 2.2 in the vehicle group, 10.4 ± 2.5 in the 0.05% CsA group, 10.4 ± 1.9 in the 2.5 mg / kg oral SodA2 group, 9.9 ± 2.5 in the 5 mg / kg oral SodA2 group, and 10.1 ± 2.9 in the 10 mg / kg oral SodA2 group.
[0112] On the 10th day of administration, the scores were 3.6±1.4 in the UT group, 14.1±1.8 in the EDE group, 13.5±1.6 in the vehicle group, 8.9±2 in the 0.05% CsA group, 8.8±2 in the 2.5 mg / kg oral SodA2 group, 7.8±1.9 in the 5 mg / kg oral SodA2 group, and 8.2±1.9 in the 10 mg / kg oral SodA2 group.
[0113] On days 5 and 10 of administration, a significant decrease in corneal fluorescent staining score was observed in all groups treated with 0.05% CsA, 2.5 mg / kg oral SodA2, 5 mg / kg oral SodA2, and 10 mg / kg oral SodA2 compared to the EDE and vehicle groups, and the 5 mg / kg oral SodA2 group in particular showed a more significant decrease than the 0.05% CsA group. The results of measuring the corneal fluorescent staining score are shown in Figure 8.
[0114] Malondialdehyde (MDA) concentration The MDA concentrations in the cornea, conjunctiva, and lacrimal gland were measured and are shown in Table 8. The unit is pmol / ml.
[0115] [Table 8]
[0116] As shown in Table 8, the concentration of MDA was decreased in the cornea, conjunctiva, and lacrimal gland in the CsA and oral SodA2 treatment groups compared to the EDE and vehicle groups. In particular, 10 mg / kg oral SodA2 showed efficacy equivalent to (cornea, lacrimal gland) or greater than (conjunctiva) 0.05% CsA.
[0117] Inflammatory cytokines The results of measuring inflammatory cytokines in the cornea and conjunctiva are shown in Table 9. The unit is pg / ml. [Table 9]
[0118] As shown in Table 9, the concentrations of IFN-γ, IL-1β, and TNF-α in the cornea and conjunctiva of the CsA and oral SodA2 treatment groups tended to be reduced compared to the EDE and vehicle groups. In particular, oral SodA2 at all doses tended to reduce inflammatory cytokines more than CsA.
[0119] Measure immune cell (CD4+IFN-γ T cells) count by flow cytometry The percentage of CD4+IFN-γ+ T cells in the cornea was 16.53±1.65% in the UT group, 48.39±1.34% in the EDE group, 47.02±0.04% in the vehicle group, 26.05±0.18% in the 0.05% CsA group, 21.18±0.15% in the 2.5 mg / kg oral SodA2 group, 23.87±0.17% in the 5 mg / kg oral SodA2 group, and 30.24±1.33% in the 10 mg / kg oral SodA2 group.
[0120] On the other hand, the percentage of CD4+IFN-γ+ T cells in the conjunctiva was 17.40±3.43% in the UT group, 46.63±1.27% in the EDE group, 43.65±2.68% in the vehicle group, 22.67±0.47% in the 0.05% CsA group, 21.00±0.63% in the 2.5 mg / kg oral SodA2 group, 22.87±2.47% in the 5 mg / kg oral SodA2 group, and 25.83±0.27% in the 10 mg / kg oral SodA2 group.
[0121] In the cornea and conjunctiva, the percentage of CD4+IFN-γ+ T cells was significantly decreased in both CsA and oral SodA2 compared to the EDE and vehicle groups, and in particular in the cornea, the percentage of CD4+IFN-γ+ T cells was significantly lower in the 2.5 mg / kg oral SodA2 group compared to the 0.05% CsA group. The results of analyzing the number of CD4+IFN-γ+ T cells in the cornea and conjunctiva are shown in Figures 9a and 9b, respectively.
[0122] Measurement of active oxygen The generation of reactive oxygen species in the cornea due to dry eye was 33.93±24.62% in the UT group, 87.43±49.83% in the EDE group, 76.25±49.54% in the vehicle group, 50.27±11.27% in the 0.05% CsA group, 33.57±26.51% in the 2.5 mg / kg oral SodA2 group, 54.53±13.53% in the 5 mg / kg oral SodA2 group, and 57.38±23.43% in the 10 mg / kg oral SodA2 group.
[0123] In the conjunctiva, the rates were 42.25 ± 23.23% in the UT group, 97.69 ± 54.19% in the EDE group, 95.48 ± 54.54% in the vehicle group, 58.16 ± 5.54% in the 0.05% CsA group, 55.13 ± 7.41% in the 2.5 mg / kg oral SodA2 group, 57.63 ± 8.16% in the 5 mg / kg oral SodA2 group, and 53.29 ± 1.19% in the 10 mg / kg oral SodA2 group.
[0124] On the other hand, in the lacrimal gland, the rates were 36.88±26.91% in the UT group, 100.90±80.95% in the EDE group, 114.26±65.19% in the vehicle group, 58.66±11.11% in the 0.05% CsA group, 59.05±10.77% in the 2.5 mg / kg oral SodA2 group, 56.03±6.37% in the 5 mg / kg oral SodA2 group, and 49.92±4.19% in the 10 mg / kg oral SodA2 group.
[0125] In the cornea, conjunctiva, and lacrimal gland, the SodA2 treatment group showed a similar or greater reduction in activity than the CsA treatment group, and in particular in the cornea, the 2.5 mg / kg oral SodA2 group showed a greater reduction in reactive oxygen species generation than the CsA group. The results for reactive oxygen species generation in the cornea, conjunctiva, and lacrimal gland are shown in Figures 10a, 10b, and 10c, respectively.
[0126] Conjunctival goblet cell count The number of goblet cells in the conjunctiva was 52.1±9.6 cells / 100μm in the UT group, 14.1±3.6 cells / 100μm in the EDE group, and 14.6±2.4 cells / 100μm in the vehicle group. The numbers were 25.2±3.4 cells / 100μm in the 0.05% CsA group, 27.9±6.9 cells / 100μm in the 2.5mg / kg oral SodA2 group, 35.8±10.2 cells / 100μm in the 5mg / kg oral SodA2 group, and 32.2±3.9 cells / 100μm in the 10mg / kg oral SodA2 group, showing a significant increase in the number of goblet cells in all treatment groups. In particular, the number of goblet cells was significantly increased in the 5mg / kg oral SodA2 group compared to the 0.05% CsA group. The results of measuring the number of goblet cells in the conjunctiva are shown in FIG. 11a (PAS stained image) and FIG. 11b (goblet cell number).
[0127] Measurement of cell death The number of necrotic cells in the cornea was significantly increased by dry eye stimulation (1.6±0.5 cells / 100 μm in the UT group, 14.8±3.3 cells / 100 μm in the EDE group, and 12.1±3.0 cells / 100 μm in the vehicle group). On the other hand, the number of dead cells in the cornea was significantly decreased in all CsA and oral SodA2 groups compared with the EDE and vehicle groups (6.1±2.1 cells / 100 μm in the 0.05% CsA group, 6.2±1.1 cells / 100 μm in the 2.5 mg / kg oral SodA2 group, 4.0±1.3 cells / 100 μm in the 5 mg / kg oral SodA2 group, and 4.6±1.3 cells / 100 μm in the 10 mg / kg oral SodA2 group). The results of such cell death measurements are shown in FIG. 12a (TUNEL staining images) and FIG. 12b (cell death positive cell counts).
[0128] Example 4.4. Conclusion In summary, oral SodA2 improved the tear secretion volume, tear film break-up time, and corneal epithelial damage of the ocular surface in mice with induced dry eye. It also showed a tendency to reduce inflammatory T cells and cytokines in the cornea and conjunctiva. Furthermore, it was found that it can reduce oxidative stress in the cornea, conjunctiva, and lacrimal gland, increase the number of goblet cells in the conjunctiva, and reduce corneal epithelial cell death. It is also judged that oral SodA2 can show equal or superior efficacy to 0.05% cyclosporin in terms of corneal fluorochrome staining score, inflammatory T cells in the cornea, and goblet cell density in the conjunctiva. The newly developed oral SodA2 can minimize damage to the ocular surface and reduce inflammation, and is judged to be useful in the treatment of dry eye patients in the future.
Claims
1. A pharmaceutical composition for treating or preventing dry eye, comprising superoxide dismutase (SOD) as an active ingredient.
2. 2. The pharmaceutical composition of claim 1, wherein the composition exhibits one or more of the following: increased tear secretion, increased tear film breakup time, minimized ocular surface damage, protection of conjunctival goblet cells, reduced number of corneal or conjunctival immune cells or inflammatory cytokines, reduced oxidative stress in the cornea, conjunctiva or lacrimal gland, and reduced corneal epithelial cell death.
3. The pharmaceutical composition of claim 1 , wherein the SOD is an isolated or purified enzyme.
4. The pharmaceutical composition according to claim 1 , wherein the SOD is in the form of a strain lysate, a strain culture, a strain culture concentrate, a strain culture extract, or a dried form thereof.
5. The pharmaceutical composition according to claim 1, wherein the SOD is Mn-SOD.
6. The pharmaceutical composition according to claim 1, wherein the SOD is a deamidated Mn-SOD.
7. The pharmaceutical composition of claim 1 , wherein the SOD is derived from a Bacillus species strain.
8. The pharmaceutical composition of claim 1 , wherein the SOD is derived from Bacillus amyloliquefaciens strain GF423 (KCTC 13222 BP).
9. The pharmaceutical composition according to claim 1, wherein the SOD has amino acid residues at positions 73 and 136 substituted with Asp based on SEQ ID NO:
2.
10. The pharmaceutical composition of claim 1 , wherein the SOD has an amino acid sequence as set forth in SEQ ID NO:
4.
11. The pharmaceutical composition of claim 1 , wherein the dry eye is Sjogren's syndrome or non-Sjogren's syndrome dry eye.
12. The pharmaceutical composition of claim 1 , wherein the composition is administered orally.
13. The pharmaceutical composition according to claim 12 , wherein the composition comprises an SOD coated with a coating agent.
14. The pharmaceutical composition of claim 13, wherein the coating agent comprises shellac.
15. A veterinary composition for treating or preventing dry eye, comprising superoxide dismutase (SOD) as an active ingredient.
16. A food composition for improving or preventing dry eye, comprising superoxide dismutase (SOD) as an active ingredient.
17. A feed composition for improving or preventing dry eye, comprising superoxide dismutase (SOD) as an active ingredient.
18. A method for preventing or treating dry eye, comprising the step of administering to a subject the pharmaceutical composition or superoxide dismutase (SOD) according to any one of claims 1 to 14.
19. 15. Use of the pharmaceutical composition or superoxide dismutase (SOD) according to any one of claims 1 to 14 for preventing or treating dry eye.
20. Use of the pharmaceutical composition or superoxide dismutase (SOD) according to any one of claims 1 to 14 for the manufacture of a medicament for preventing or treating dry eye.
Citation Information
Patent Citations
Use of antioxidants in the manufacture of therapeutic and / or prophylactic agents for ocular surface abnormalities
JP2004537522A
Bacillus amyloliquefaciens GF423 strain and compositions for providing antioxidant and anti-inflammatory activity or preventing or treating dyslipidemia, comprising polypeptides produced thereby
JP2020513781A
Composition for preventing or treating dry eye syndrome comprising SOD3
KR101966330B1
Pharmaceutical composition for eye disease containing superoxide dismutase fusion protein
KR1020120093541A
Methods of treating xerostomia and xerophthalmia
WO2004087873A2
